

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: KATO, et al. :
APPLICATION NO.: 10/595948 : Examiner: To be assigned
INTERNATIONAL FILING DATE: 10 NOV 2004 : Group Art Unit: 1614
TITLE: Quinolonecarboxylic Acid Compounds Having 5- :
HT4 Receptor Agonistic Activity :

Commissioner for Patents
Via EFS

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office the documents cited in the attached PTO-FB-A820, copies of which are enclosed (other than U.S. patent documents).

The Examiner is respectfully requested to consider the cited document(s) in connection with the present application in accord with 37 CFR § 1.104(a), and to indicate such by returning a signed and initialed copy of the FB-A820 and listing the document(s) in the "References Cited" portion of any patent(s) issuing from this application or child application(s) thereof.


No fee is believed to be due because an Office Action on the merits has not been mailed. However, the Commissioner is authorized to charge any fees that may be required, or credit any overpayment, to Deposit Account No. 16-1445.

The Examiner is invited to contact the undersigned with any questions.

Date:

31 August 06

Respectfully submitted,


Frank W. Forman
Attorney for Applicant(s)
Reg. No. 42,547

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5669
Frank.W.Forman@pfizer.com